COMMUNIQUÉS West-GlobeNewswire

deepull appoints Didier Deltort to its Board of Directors

22/05/2024 - 09:00

deepull appoints Didier Deltort to its Board of Directors Barcelona, Spain – 22 May 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis [...]

Arbutus to Present Imdusiran Data at EASL Congress 2024

22/05/2024 - 08:00

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to [...]

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

22/05/2024 - 08:00

PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]

NANOBIOTIX fait le point sur ses résultats financiers et opérationnels du premier trimestre 2024

22/05/2024 - 08:00

PARIS et CAMBRIDGE, Mass., 22 mai 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

22/05/2024 - 07:30

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET - [...]

OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et métaboliques

22/05/2024 - 07:30

OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et métaboliques Nantes, France et [...]

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

22/05/2024 - 07:00

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® [...]

Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®

22/05/2024 - 07:00

PRESS RELEASE: REGULATED INFORMATION – INSIDE INFORMATION 22 MAY 2024, 07:00 CEST Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump® Positive and collaborative [...]

Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

22/05/2024 - 07:00

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke. 1 The Roche Diagnostics Tina-quant® Lp(a) [...]

Predicine to Present 9 Liquid Biopsy Studies at ASCO 2024

22/05/2024 - 06:11

HAYWARD, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 9 ctDNA studies at ASCO 2024, spotlighting the clinical utility of [...]

Deenova enters Belgian market with tender win at AZ Saint Lucas Hospital

22/05/2024 - 06:00

MILAN, Italy, May 22, 2024 (GLOBE NEWSWIRE) -- Deenova , the European leader in pharmacy automation, is thrilled to announce its successful tender win at AZ Saint Lucas Hospital in Brugge, facilitated by its business [...]

Deenova entre sur le marché belge avec une victoire aux enchères à l'hôpital AZ Saint Lucas

22/05/2024 - 06:00

MILAN, Italie, 22 mai 2024 (GLOBE NEWSWIRE) -- Deenova , le leader européen de l'automatisation pharmaceutique, est ravi d'annoncer l’attribution de l’appel d’offres pour l’automatisation de la pharmacie de l'hôpital AZ [...]

LifeStance Health Group Announces Pricing of Secondary Public Offering

22/05/2024 - 05:43

SCOTTSDALE, Ariz., May 21, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

22/05/2024 - 02:39

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]

APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy

22/05/2024 - 02:00

Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for APRINOIA’s planned Phase 3 study of APN-1607 (florzolotau (18F)) in [...]

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

22/05/2024 - 00:50

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the [...]

Nature Medicine se réjouit de partager l’amélioration significative de la fonction de la main et du bras après une lésion de la moelle épinière grâce à la thérapie ONWARD® ARC-EX® Therapy

21/05/2024 - 23:53

La thérapie ARC Therapy™ s’est révélée sûre et efficace dans le cadre d’une étude pivot mondiale* Quatre-vingt-dix pour cent des participants ont amélioré la force ou la fonction de leurs membres supérieurs* [...]

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program

21/05/2024 - 23:25

COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 8, 2024, has now been terminated, as the intended number of shares [...]

LeMaitre to Present at the Jefferies Global Healthcare Conference

21/05/2024 - 23:16

BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on [...]